What we have learned about pancreatic cancer from mouse models

Gastroenterology

Volumn 142, Issue 5, 2012, Pages 1079-1092

  Pérez Mancera, Pedro A ^a   Guerra, Carmen ^b   Barbacid, Mariano ^b   Tuveson, David A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

18F fluoro 2 deoxyglucose positron emission tomography; computed tomography; COX; CT; cyclooxygenase; FDG PET; GEMM; genetically engineered mouse model; intraductal papillary mucinous neoplasm; IPMN; MAPK; MCN; mitogen activated protein kinase; mucinous cystic neoplasm; pancreatic ductal adenocarcinoma; pancreatic intraepithelial neoplasia; PanIN; PDA; phosphatidylinositol 3 kinase; PI3K; TGF; transforming growth factor

Indexed keywords

B RAF KINASE; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTERLEUKIN 6; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISOLONE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STAT3 PROTEIN; SULINDAC; SUPPRESSOR OF CYTOKINE SIGNALING 3; TEMSIROLIMUS; TIPIFARNIB; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR PDX 1; UNINDEXED DRUG;

ACINAR CELL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; EARLY DIAGNOSIS; ENZYME ACTIVATION; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GASTROENTEROLOGY; GENE FREQUENCY; HUMAN; INFLAMMATION; LOSS OF FUNCTION MUTATION; MACROPHAGE; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CARCINOMA; PANCREATITIS; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84860112131     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.03.002     Document Type: Review

References (138)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. D.M. Ornitz, R.E. Hammer, A. Messing Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice Science 238 1987 188 193
3. C.J. Quaife, C.A. Pinkert, D.M. Ornitz Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice Cell 48 1987 1023 1034
4. S.R. Hingorani, E.F. Petricoin, A. Maitra Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
5. E.L. Jackson, N. Willis, K. Mercer Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras Genes Dev 15 2001 3243 3248
6. R.H. Hruban, M. Goggins, J. Parsons Progression model for pancreatic cancer Clin Cancer Res 6 2000 2969 2972
7. R.H. Hruban, R.E. Wilentz, S.E. Kern Genetic progression in the pancreatic ducts Am J Pathol 156 2000 1821 1825
8. C. Caldas, S.A. Hahn, L.T. da Costa Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1994 27 32
9. M.S. Redston, C. Caldas, A.B. Seymour p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res 54 1994 3025 3033
10. S.A. Hahn, M. Schutte, A.T. Hoque DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 271 1996 350 353
11. M. Goggins, M. Shekher, K. Turnacioglu Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas Cancer Res 58 1998 5329 5332
12. A.J. Aguirre, N. Bardeesy, M. Sinha Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev 17 2003 3112 3126
13. N. Bardeesy, A.J. Aguirre, G.C. Chu Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse Proc Natl Acad Sci U S A 103 2006 5947 5952
14. S.R. Hingorani, L. Wang, A.S. Multani Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Cancer Cell 7 2005 469 483
15. H. Ijichi, A. Chytil, A.E. Gorska Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression Genes Dev 20 2006 3147 3160
16. E.A. Collisson, A. Sadanandam, P. Olson Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat Med 17 2011 500 503
17. A. Maitra, N. Fukushima, K. Takaori Precursors to invasive pancreatic cancer Adv Anat Pathol 12 2005 81 91
18. N. Bardeesy, K.H. Cheng, J.H. Berger Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer Genes Dev 20 2006 3130 3146
19. K. Izeradjene, C. Combs, M. Best Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas Cancer Cell 11 2007 229 243
20. J.T. Siveke, H. Einwachter, B. Sipos Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN Cancer Cell 12 2007 266 279
21. D.F. Vincent, K.P. Yan, I. Treilleux Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas PLoS Genet 5 2009 e1000575
22. P.J. Grippo, D.A. Tuveson Deploying mouse models of pancreatic cancer for chemoprevention studies Cancer Prev Res (Phila) 3 2010 1382 1387
23. P.K. Mazur, J.T. Siveke Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology Gut 2011 Aug 26 [Epub ahead of print]
24. A. Neesse, P. Michl, K.K. Frese Stromal biology and therapy in pancreatic cancer Gut 60 2011 861 868
25. C.S. Branda, S.M. Dymecki Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice Dev Cell 6 2004 7 28
26. F.H. Brembeck, F.S. Schreiber, T.B. Deramaudt The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice Cancer Res 63 2003 2005 2009
27. C. Guerra, A.J. Schuhmacher, M. Canamero Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice Cancer Cell 11 2007 291 302
28. L. Zhu, G. Shi, C.M. Schmidt Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia Am J Pathol 171 2007 263 273
29. N. Habbe, G. Shi, R.A. Meguid Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice Proc Natl Acad Sci U S A 105 2008 18913 18918
30. LP O. De La, L.L. Emerson, J.L. Goodman Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia Proc Natl Acad Sci U S A 105 2008 18907 18912
31. M. Wagner, F.R. Greten, C.K. Weber A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease Genes Dev 15 2001 286 293
32. H.C. Crawford, C.R. Scoggins, M.K. Washington Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas J Clin Invest 109 2002 1437 1444
33. B.Z. Stanger, B. Stiles, G.Y. Lauwers Pten constrains centroacinar cell expansion and malignant transformation in the pancreas Cancer Cell 8 2005 185 195
34. M. Rovira, S.G. Scott, A.S. Liss Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas Proc Natl Acad Sci U S A 107 2010 75 80
35. S.Y. Gidekel Friedlander, G.C. Chu, E.L. Snyder Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras Cancer Cell 16 2009 379 389
36. C. Guerra, M. Collado, C. Navas Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence Cancer Cell 19 2011 728 739
37. K. Furuyama, Y. Kawaguchi, H. Akiyama Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine Nat Genet 43 2011 34 41
38. J.P. Morris IV, D.A. Cano, S. Sekine Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice J Clin Invest 120 2010 508 520
39. N. Douziech, A. Lajas, Z. Coulombe Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines Endocrine 9 1998 171 183
40. M. Collado, J. Gil, A. Efeyan Tumour biology: senescence in premalignant tumours Nature 436 2005 642
41. M.E. Caldwell, G.M. Denicola, C.P. Martins Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer Oncogene 31 2012 1599 1608
42. M. Bonifazi, S. Gallus, C. Bosetti Aspirin use and pancreatic cancer risk Eur J Cancer Prev 19 2010 352 354
43. M.C. Bradley, C.M. Hughes, M.M. Cantwell Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study Br J Cancer 102 2010 1415 1421
44. P.M. Rothwell, F.G. Fowkes, J.F. Belch Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
45. K.E. Lee, D. Bar-Sagi Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells Cancer Cell 18 2010 448 458
46. A. Fukuda, S.C. Wang, J.P. Morris IV Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression Cancer Cell 19 2011 441 455
47. M. Lesina, M.U. Kurkowski, K. Ludes Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer Cancer Cell 19 2011 456 469
48. R.B. Corcoran, G. Contino, V. Deshpande STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis Cancer Res 71 2011 5020 5029
49. J.L. Bos ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
50. K. Rajalingam, R. Schreck, U.R. Rapp Ras oncogenes and their downstream targets Biochim Biophys Acta 1773 2007 1177 1195
51. S. Schubbert, K. Shannon, G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
52. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
53. N. Mitin, K.L. Rossman, C.J. Der Signaling interplay in Ras superfamily function Curr Biol 15 2005 R563 R574
54. M.T. Yip-Schneider, A. Lin, D. Barnard Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression Int J Oncol 15 1999 271 279
55. M.T. Yip-Schneider, A. Lin, M.S. Marshall Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2 Biochem Biophys Res Commun 280 2001 992 997
56. K.S. Chadha, T. Khoury, J. Yu Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma Ann Surg Oncol 13 2006 933 939
57. E.S. Calhoun, J.B. Jones, R. Ashfaq BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets Am J Pathol 163 2003 1255 1260
58. W. Kolch Coordinating ERK/MAPK signalling through scaffolds and inhibitors Nat Rev Mol Cell Biol 6 2005 827 837
59. P.J. Roberts, C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
60. M.R. Junttila, S.P. Li, J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J 22 2008 954 965
61. R.B. Blasco, S. Francoz, D. Santamaria c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma Cancer Cell 19 2011 652 663
62. F.A. Karreth, K.K. Frese, G.M. Denicola C-Raf is required for the initiation of lung cancer by K-Ras Cancer Discov 1 2011 128 136
63. M. Huser, J. Luckett, A. Chiloeches MEK kinase activity is not necessary for Raf-1 function EMBO J 20 2001 1940 1951
64. M. Mikula, M. Schreiber, Z. Husak Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene EMBO J 20 2001 1952 1962
65. A. Hindley, W. Kolch Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases J Cell Sci 115 2002 1575 1581
66. M.A. White, C. Nicolette, A. Minden Multiple Ras functions can contribute to mammalian cell transformation Cell 80 1995 533 541
67. P. Rodriguez-Viciana, P.H. Warne, A. Khwaja Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras Cell 89 1997 457 467
68. J. Luo, B.D. Manning, L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 2003 257 262
69. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
70. A.L. Kennedy, J.P. Morton, I. Manoharan Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis Mol Cell 42 2011 36 49
71. M. Preis, M. Korc Kinase signaling pathways as targets for intervention in pancreatic cancer Cancer Biol Ther 9 2010 754 763
72. J.Q. Cheng, B. Ruggeri, W.M. Klein Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci U S A 93 1996 3636 3641
73. B.A. Ruggeri, L. Huang, M. Wood Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas Mol Carcinog 21 1998 81 86
74. D.A. Altomare, S. Tanno, A. De Rienzo Frequent activation of AKT2 kinase in human pancreatic carcinomas J Cell Biochem 87 2002 470 476
75. M.G. Schlieman, B.N. Fahy, R. Ramsamooj Incidence, mechanism and prognostic value of activated AKT in pancreas cancer Br J Cancer 89 2003 2110 2115
76. T. Asano, Y. Yao, J. Zhu The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells Oncogene 23 2004 8571 8580
77. F. Schonleben, W. Qiu, N.T. Ciau PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas Clin Cancer Res 12 2006 3851 3855
78. R. Hill, J.H. Calvopina, C. Kim PTEN loss accelerates KrasG12D-induced pancreatic cancer development Cancer Res 70 2010 7114 7124
79. X. Xu, B. Ehdaie, N. Ohara Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice Oncogene 29 2010 674 686
80. H. Ying, K.G. Elpek, A. Vinjamoori Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network Cancer Discov 1 2011 158 169
81. N.M. Hamad, J.H. Elconin, A.E. Karnoub Distinct requirements for Ras oncogenesis in human versus mouse cells Genes Dev 16 2002 2045 2057
82. A. Rangarajan, S.J. Hong, A. Gifford Species- and cell type-specific requirements for cellular transformation Cancer Cell 6 2004 171 183
83. K.H. Lim, A.T. Baines, J.J. Fiordalisi Activation of RalA is critical for Ras-induced tumorigenesis of human cells Cancer Cell 7 2005 533 545
84. K.H. Lim, K. O'Hayer, S.J. Adam Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells Curr Biol 16 2006 2385 2394
85. G. Feldmann, A. Mishra, S.M. Hong Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling Cancer Res 70 2010 4460 4469
86. S. Jones, X. Zhang, D.W. Parsons Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
87. J. Jonkers, A. Berns Retroviral insertional mutagenesis as a strategy to identify cancer genes Biochim Biophys Acta 1287 1996 29 57
88. A.G. Uren, J. Kool, A. Berns Retroviral insertional mutagenesis: past, present and future Oncogene 24 2005 7656 7672
89. J. Kool, A. Berns High-throughput insertional mutagenesis screens in mice to identify oncogenic networks Nat Rev Cancer 9 2009 389 399
90. C.M. Carlson, J.L. Frandsen, N. Kirchhof Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse Proc Natl Acad Sci U S A 102 2005 17059 17064
91. L.S. Collier, C.M. Carlson, S. Ravimohan Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse Nature 436 2005 272 276
92. A.J. Dupuy, K. Akagi, D.A. Largaespada Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system Nature 436 2005 221 226
93. V.W. Keng, A. Villanueva, D.Y. Chiang A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma Nat Biotechnol 27 2009 264 274
94. T.K. Starr, R. Allaei, K.A. Silverstein A transposon-based genetic screen in mice identifies genes altered in colorectal cancer Science 323 2009 1747 1750
95. R. Rad, L. Rad, W. Wang PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice Science 330 2010 1104 1107
96. Z. Ivics, P.B. Hackett, R.H. Plasterk Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells Cell 91 1997 501 510
97. S. Ding, X. Wu, G. Li Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice Cell 122 2005 473 483
98. N.G. Copeland, N.A. Jenkins Harnessing transposons for cancer gene discovery Nat Rev Cancer 10 2010 696 706
99. V.M. Faca, K.S. Song, H. Wang A mouse to human search for plasma proteome changes associated with pancreatic tumor development PLoS Med 5 2008 e123
100. K.A. Kelly, N. Bardeesy, R. Anbazhagan Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma PLoS Med 5 2008 e85
101. K.P. Olive, D.A. Tuveson The use of targeted mouse models for preclinical testing of novel cancer therapeutics Clin Cancer Res 12 2006 5277 5287
102. K.P. Olive, M.A. Jacobetz, C.J. Davidson Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461
103. V. Fendrich, R. Schneider, A. Maitra Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer Neoplasia 13 2011 180 186
104. H.A. Burris III, M.J. Moore, J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
105. M. Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605 1617
106. M.J. Moore, D. Goldstein, J. Hamm Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966
107. D.D. Von Hoff, R.K. Ramanathan, M.J. Borad Gemcitabine Plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J Clin Oncol 29 2011 4548 4554
108. T. Conroy, F. Desseigne, M. Ychou Folfirinox versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
109. D.A. Richards, P.R. Kuefler, C. Becerra Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study Invest New Drugs 29 2011 144 153
110. B.M. Wolpin, A.F. Hezel, T. Abrams Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer J Clin Oncol 27 2009 193 198
111. M.M. Javle, R.T. Shroff, H. Xiong Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies BMC Cancer 10 2010 368
112. E. Van Cutsem, H. van de Velde, P. Karasek Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430 1438
113. H.L. Kindler, K. Wroblewski, J.A. Wallace Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium Invest New Drugs 39 2012 382 386
114. P.J. Campbell, S. Yachida, L.J. Mudie The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
115. S. Yachida, S. Jones, I. Bozic Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 2010 1114 1117
116. T.E. Bapiro, F.M. Richards, M.A. Goldgraben A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy Cancer Chemother Pharmacol 68 2011 1243 1253
117. G. Feldmann, N. Habbe, S. Dhara Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer Gut 57 2008 1420 1430
118. G.L. Beatty, E.G. Chiorean, M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
119. H. Ijichi, A. Chytil, A.E. Gorska Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma J Clin Invest 121 2011 4106 4117
120. H. Funahashi, M. Satake, D. Dawson Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor Cancer Res 67 2007 7068 7071
121. R. Plentz, J.S. Park, A.D. Rhim Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma Gastroenterology 136 2009 1741 1749 e6
122. A. Mohammed, N.B. Janakiram, Q. Li The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model Cancer Prev Res 3 2010 1417 1426
123. K.T. Liby, D.B. Royce, R. Risingsong Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer Cancer Prev Res 3 2010 1427 1434
124. V. Fendrich, N.M. Chen, M. Neef The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer Gut 59 2010 630 637
125. A.F. Hezel, S. Gurumurthy, Z. Granot Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms Mol Cell Biol 28 2008 2414 2425
126. J.P. Morton, N.B. Jamieson, S.A. Karim LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest Gastroenterology 139 2010 586 597 597 e1-6
127. F. Skoulidis, L.D. Cassidy, V. Pisupati Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer Cancer Cell 18 2010 499 509
128. M. Rowley, A. Ohashi, G. Mondal Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice Gastroenterology 140 2011 1303 1313 e1-3
129. G. Feldmann, C. Karikari, M. dal Molin Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer Cancer Biol Ther 11 2011 959 968
130. R. Shakya, L.J. Reid, C.R. Reczek BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity Science 334 2011 525 528
131. P.K. Mazur, H. Einwachter, M. Lee Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma Proc Natl Acad Sci U S A 107 2010 13438 13443
132. L. Hanlon, J.L. Avila, R.M. Demarest Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma Cancer Res 70 2010 4280 4286
133. M. Pasca di Magliano, S. Sekine, A. Ermilov Hedgehog/Ras interactions regulate early stages of pancreatic cancer Genes Dev 20 2006 3161 3173
134. P.W. Heiser, D.A. Cano, L. Landsman Stabilization of beta-catenin induces pancreas tumor formation Gastroenterology 135 2008 1288 1300
135. T.L. Tinder, D.B. Subramani, G.D. Basu MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma J Immunol 181 2008 3116 3125
136. I. Heid, C. Lubeseder-Martellato, B. Sipos Early requirement of Rac1 in a mouse model of pancreatic cancer Gastroenterology 141 2011 719 730 730 e1-7
137. C. Carriere, A.J. Gore, A.M. Norris Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions Gastroenterology 141 2011 1091 1101
138. E. Maniati, M. Bossard, N. Cook Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice J Clin Invest 121 2011 4685 4699